A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors

Trial Profile

A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Pancrelipase (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacodynamics
  • Sponsors AbbVie
  • Most Recent Events

    • 19 Sep 2016 Status changed from recruiting to completed.
    • 22 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 22 Dec 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top